MAIA Biotechnology, Inc. (MAIA) 10-Year Financial Performance & Capital Metrics

MAIA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutMAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.Show more

Revenue $0
EBITDA -$23M -17.6%
Net Income -$23M -17.6%
EPS (Diluted) -1.05 +29.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -1131.02% -157.0%
ROIC -
Debt/Equity -
Interest Coverage -297494.91

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 67.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM13.88%

EPS CAGR

10Y-

5Y-

3Y-

TTM44.03%

ROCE

10Y Avg-832.01%

5Y Avg-896.63%

3Y Avg-304.58%

Latest-378.72%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-
Operating Expenses+	6.92M	6.98M	7.79M	16.18M	20.18M	16.96M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	5.01M	5.56M	4.29M	6.14M	9.07M	6.95M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	1.91M	1.41M	3.45M	8.93M	11.11M	10.01M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	43.67K	1.1M	0	0
Operating Income+	-6.92M	-6.98M	-7.79M	-16.18M	-20.18M	-16.96M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-0.01%	-0.12%	-1.08%	-0.25%	0.16%
EBITDA+	0	0	-11.75M	-15.76M	-19.77M	-23.25M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-	-	-0.34%	-0.25%	-0.18%
D&A (Non-Cash Add-back)	6.92M	6.98M	0	0	0	0
EBIT	-6.92M	-6.98M	-11.75M	-15.76M	-19.77M	-23.25M
Net Interest Income+	242	-31.55K	-825.53K	-5.1K	27.63K	318.31K
Interest Income	242	-	2.01K	1.87K	27.63K	318.37K
Interest Expense	-	31.55K	827.54K	6.97K	0	57
Other Income/Expense	242	16.35K	-4.79M	406.92K	409.48K	-6.3M
Pretax Income+	-6.92M	-6.96M	-12.58M	-15.77M	-19.77M	-23.25M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	0.94%	0.95%	0.99%	1%	1%	1%
Net Income+	-6.49M	-6.64M	-12.5M	-15.77M	-19.77M	-23.25M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-0.02%	-0.88%	-0.26%	-0.25%	-0.18%
Net Income (Continuing)	-6.92M	-6.96M	-12.58M	-15.77M	-19.77M	-23.25M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	1.5M	1.72M	0	0	0	0
EPS (Diluted)+	-0.61	-0.62	-1.18	-1.70	-1.49	-1.05
EPS Growth %	-	-0.02%	-0.9%	-0.44%	0.12%	0.3%
EPS (Basic)	-0.61	-0.62	-1.18	-1.70	-1.49	-1.05
Diluted Shares Outstanding	10.64M	10.64M	10.64M	9.28M	13.26M	22.2M
Basic Shares Outstanding	10.64M	10.64M	10.64M	9.28M	13.26M	22.2M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.73M	746.5K	10.67M	11.81M	7.56M	10.15M
Cash & Short-Term Investments	1.71M	663.46K	10.57M	10.95M	7.15M	9.6M
Cash Only	1.71M	663.46K	10.57M	10.95M	7.15M	9.6M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	0	0	43.67K	302.79K	144.68K	77.35K
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	-43.67K	554.32K	268.68K	473.83K
Total Non-Current Assets+	0	0	654.7K	214K	2.8K	2.8K
Property, Plant & Equipment	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	0	654.7K	214K	2.8K	2.8K
Total Assets+	1.73M	746.5K	11.33M	12.02M	7.57M	10.16M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	-0.57%	14.17%	0.06%	-0.37%	0.34%
Total Current Liabilities+	374.56K	1.69M	2.15M	3.27M	4.94M	3.83M
Accounts Payable	169.19K	154.89K	960.4K	1.17M	1.64M	1.51M
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	25K	31.95K	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	2.1K	1.44M	496.02K	0	1.61M	941.1K
Current Ratio	4.63x	0.44x	4.97x	3.61x	1.53x	2.65x
Quick Ratio	4.63x	0.44x	4.97x	3.61x	1.53x	2.65x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	35.17K	669.06K	0	245.34K	2.15M	2.69M
Long-Term Debt	9.17K	431.8K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	26K	237.26K	0	245.34K	2.15M	2.69M
Total Liabilities	409.74K	2.36M	2.15M	3.51M	7.09M	6.52M
Total Debt+	34.17K	463.75K	0	0	0	0
Net Debt	-1.68M	-199.7K	-10.57M	-10.95M	-7.15M	-9.6M
Debt / Equity	0.03x	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-221.12x	-9.41x	-2321.83x	-	-297494.91x
Total Equity+	1.32M	-1.62M	9.18M	8.51M	477.51K	3.63M
Equity Growth %	-	-2.22%	6.68%	-0.07%	-0.94%	6.61%
Book Value per Share	0.12	-0.15	0.86	0.92	0.04	0.16
Total Shareholders' Equity	-172.87K	-3.34M	9.18M	8.51M	477.51K	3.63M
Common Stock	442	443	758	1.1K	1.7K	2.62K
Retained Earnings	-9.3M	-15.93M	-28.44M	-44.21M	-63.98M	-87.23M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-104.4K	0	0	-15.97K	-16.26K	-30.61K
Minority Interest	1.5M	1.72M	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.57M	-1.84M	-4.12M	-12.1M	-13.07M	-15.7M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-0.18%	-1.24%	-1.93%	-0.08%	-0.2%
Net Income	-6.49M	-6.96M	-12.58M	-15.77M	-19.77M	-23.25M
Depreciation & Amortization	0	0	0	0	0	0
Stock-Based Compensation	0	3.89M	2.72M	2.32M	3.09M	1.91M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	4.66M	-28.02K	4.61M	1M	526.53K	6.88M
Working Capital Changes	269.46K	1.25M	1.13M	352.78K	3.09M	-1.24M
Change in Receivables	0	0	0	-269.39K	158.41K	56.8K
Change in Inventory	0	0	0	0	0	0
Change in Payables	104.83K	-2.3K	805.52K	211.35K	471.9K	-118.83K
Cash from Investing+	187.56K	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	2.22M	798.05K	14.03M	12.48M	9.27M	18.18M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	125K	79.19K	860.43K	-1.5M	-2.15M	-578.1K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-1.57M	-1.84M	-4.12M	-12.1M	-13.07M	-15.7M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-0.18%	-1.24%	-1.93%	-0.08%	-0.2%
FCF per Share	-0.15	-0.17	-0.39	-1.30	-0.99	-0.71
FCF Conversion (FCF/Net Income)	0.24x	0.28x	0.33x	0.77x	0.66x	0.68x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-490.1%	-	-330.58%	-178.29%	-440.12%	-1131.02%
Debt / Equity	0.03x	-	-	-	-	-
Interest Coverage	-	-221.12x	-9.41x	-2321.83x	-	-297494.91x
FCF Conversion	0.24x	0.28x	0.33x	0.77x	0.66x	0.68x

Frequently Asked Questions

Growth & Financials

MAIA Biotechnology, Inc. (MAIA) grew revenue by 0.0% over the past year. Growth has been modest.

MAIA Biotechnology, Inc. (MAIA) reported a net loss of $22.3M for fiscal year 2024.

Dividend & Returns

MAIA Biotechnology, Inc. (MAIA) has a return on equity (ROE) of -1131.0%. Negative ROE indicates the company is unprofitable.

MAIA Biotechnology, Inc. (MAIA) had negative free cash flow of $15.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener